PBM
Psyence Biomedical Ltd.
Price Chart
Latest Quote
$3.07
+0.06 (+1.99%)
Current Price
| Previous Close | $3.01 |
| Open | $3.04 |
| Day High | $3.15 |
| Day Low | $2.94 |
| Volume | 88,896 |
Stock Information
| Shares Outstanding | 3.81M |
| Cash Equivalents | $7.44M |
| Net Income | $-6.94M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.95M |
| EPS (TTM) | $-12.56 |
| Exchange | NCM |
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $3.07 | 89,300 |
| 2026-07-16 | $3.01 | 375,000 |
| 2026-07-15 | $2.89 | 410,700 |
| 2026-07-14 | $2.87 | 23,700 |
| 2026-07-13 | $2.85 | 30,500 |
| 2026-07-10 | $2.97 | 28,300 |
| 2026-07-09 | $2.93 | 22,200 |
| 2026-07-08 | $2.90 | 20,400 |
| 2026-07-07 | $3.11 | 20,400 |
| 2026-07-06 | $3.06 | 13,500 |
| 2026-07-02 | $3.04 | 39,500 |
| 2026-07-01 | $3.11 | 41,600 |
| 2026-06-30 | $3.06 | 25,700 |
| 2026-06-29 | $3.10 | 35,100 |
| 2026-06-26 | $2.97 | 62,600 |
| 2026-06-25 | $2.71 | 57,400 |
| 2026-06-24 | $2.75 | 62,900 |
| 2026-06-23 | $2.91 | 25,200 |
| 2026-06-22 | $3.10 | 35,800 |
| 2026-06-18 | $3.15 | 34,400 |
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
đ° Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-04-27T13:16:01ZFDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
MT Newswires âĸ 2026-04-24T14:19:44ZPsychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
MT Newswires âĸ 2026-04-20T11:23:51ZTrump Trade: President to sign order on psychedelic used for PTSD
TipRanks âĸ 2026-04-17T21:56:03Z
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2026-04-17T19:56:32ZSector Update: Health Care Stocks Higher Friday Afternoon
MT Newswires âĸ 2026-04-17T17:44:56ZTop Midday Gainers
MT Newswires âĸ 2026-04-17T16:45:52ZPsychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
TipRanks âĸ 2026-03-06T15:15:45Z
Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session
MT Newswires âĸ 2025-12-19T14:49:31ZInvestors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session
MT Newswires âĸ 2025-12-19T13:16:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $9,522 | $9,270 | $52,941 | $0 |
| Total Expenses | $5,945,264 | $3,663,022 | $43,354,085 | $3,234,869 |
| Other Income Expense | $-1,245,005 | $4,588,295 | $-7,754,155 | $26,912 |
| Other Non Operating Income Expenses | $-110,242 | $4,063,193 | $-5,265,685 | - |
| Net Non Operating Interest Income Expense | $253,848 | $86,517 | $-50,807 | $1,554 |
| Interest Expense Non Operating | $9,522 | $9,270 | $52,941 | $0 |
| Operating Expense | $5,945,264 | $3,663,022 | $43,354,085 | $3,234,869 |
| Other Operating Expenses | $-292,247 | - | $40,602,261 | - |
| Selling And Marketing Expense | $218,485 | $483,530 | $80,603 | $7,029 |
| General And Administrative Expense | $4,547,107 | $2,833,056 | $1,716,388 | $1,618,945 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Net Interest Income | $253,848 | $86,517 | $-50,807 | $1,554 |
| Interest Income | $263,370 | $95,787 | $2,134 | $1,554 |
| Normalized Income | $-5,846,897 | $565,453 | $-48,670,578 | $-3,233,315 |
| Net Income From Continuing And Discontinued Operation | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Net Income Common Stockholders | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Net Income | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Net Income Including Noncontrolling Interests | $-6,936,421 | $1,011,790 | $-51,159,047 | $-3,206,403 |
| Net Income Continuous Operations | $-6,936,421 | $1,011,790 | $-51,159,047 | $-3,206,403 |
| Pretax Income | $-6,936,421 | $1,011,790 | $-51,159,047 | $-3,206,403 |
| Special Income Charges | $-1,500,000 | $0 | $-2,179,525 | $0 |
| Earnings From Equity Interest | $-45,239 | $0 | $0 | - |
| Interest Income Non Operating | $263,370 | $95,787 | $2,134 | $1,554 |
| Operating Income | $-5,945,264 | $-3,663,022 | $-43,354,085 | $-3,234,869 |
| Depreciation Amortization Depletion Income Statement | $5,266 | $4,268 | $240 | $0 |
| Depreciation And Amortization In Income Statement | $5,266 | $4,268 | $240 | $0 |
| Depreciation Income Statement | $5,266 | $4,268 | $240 | $0 |
| Per Share | ||||
| Diluted EPS | - | $32.76 | $-14274.29 | $-940.02 |
| Basic EPS | - | $32.76 | $-14274.29 | $-940.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $78,765 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,832,109 | $500,226 | $-48,617,396 | $-3,233,315 |
| Total Unusual Items | $-1,089,524 | $525,102 | $-2,488,470 | $26,912 |
| Total Unusual Items Excluding Goodwill | $-1,089,524 | $525,102 | $-2,488,470 | $26,912 |
| Reconciled Depreciation | $5,266 | $4,268 | $240 | $0 |
| EBITDA (Bullshit earnings) | $-6,921,633 | $1,025,328 | $-51,105,866 | $-3,206,403 |
| EBIT | $-6,926,899 | $1,021,060 | $-51,106,106 | $-3,206,403 |
| Diluted NI Availto Com Stockholders | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Other Special Charges | $1,500,000 | - | $-281,500 | - |
| Restructuring And Mergern Acquisition | $0 | $0 | $2,461,025 | $0 |
| Gain On Sale Of Security | $410,476 | $525,102 | $-308,945 | $26,912 |
| Research And Development | $1,466,653 | $342,168 | $954,593 | $1,608,895 |
| Selling General And Administration | $4,765,592 | $3,316,586 | $1,796,991 | $1,625,974 |
| Other Gand A | $4,547,107 | $2,833,056 | $1,716,388 | $1,618,945 |
| Diluted Average Shares | - | $30,887 | $3,584 | $3,411 |
| Basic Average Shares | - | $30,887 | $3,584 | $3,411 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Total Assets | $17,567,320 | $7,316,370 | $1,132,159 | $1,590,255 |
| Total Non Current Assets | $8,456,745 | $756,096 | $5,487 | $0 |
| Investmentin Financial Assets | $0 | $745,000 | $0 | - |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $0 | $745,000 | $0 | - |
| Current Assets | $9,110,575 | $6,560,274 | $1,126,672 | $1,590,255 |
| Restricted Cash | $47,191 | $35,964 | $29,611 | $29,556 |
| Prepaid Assets | $1,255,857 | $251,796 | $322,126 | $77,050 |
| Receivables | $362,764 | $137,348 | $41,747 | $149,369 |
| Other Receivables | $109,779 | $137,348 | $41,747 | $149,369 |
| Loans Receivable | $252,985 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $7,444,763 | $6,135,166 | $733,188 | $1,334,280 |
| Cash And Cash Equivalents | $7,444,763 | $6,135,166 | $733,188 | $1,334,280 |
| Cash Financial | $7,444,763 | $6,135,166 | $733,188 | $1,334,280 |
| Debt | ||||
| Net Debt | - | - | $9,714,701 | - |
| Total Debt | - | - | $10,447,889 | - |
| Current Debt And Capital Lease Obligation | - | - | $10,447,889 | - |
| Current Debt | - | - | $10,447,889 | - |
| Other Current Borrowings | - | - | $10,447,889 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $623,190 | $594,366 | $12,104,699 | $1,790,700 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $623,190 | $594,366 | $12,104,699 | $1,790,700 |
| Other Current Liabilities | $215,476 | $200,096 | $901,608 | - |
| Payables And Accrued Expenses | $314,193 | $312,418 | $688,303 | $1,790,700 |
| Payables | $229,509 | $261,937 | $562,352 | $1,628,143 |
| Accounts Payable | $229,509 | $261,937 | $562,352 | $1,628,143 |
| Equity | ||||
| Common Stock Equity | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Total Equity Gross Minority Interest | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Stockholders Equity | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Other Equity Interest | $1,183,595 | $1,065,705 | - | $-200,558 |
| Gains Losses Not Affecting Retained Earnings | $396,177 | $351,198 | $361,057 | $165,360 |
| Retained Earnings | $-63,383,625 | $-56,447,204 | $-57,458,994 | $-6,299,946 |
| Long Term Equity Investment | $8,060,928 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $2,293,277 | $90,883 | $3,584 | $3,411 |
| Share Issued | $2,293,277 | $90,883 | $3,584 | $3,411 |
| Tangible Book Value | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Invested Capital | $16,944,130 | $6,722,004 | $-524,651 | $-200,445 |
| Working Capital | $8,487,385 | $5,965,908 | $-10,978,027 | $-200,445 |
| Total Capitalization | $16,944,130 | $6,722,004 | $-10,972,540 | $-200,445 |
| Capital Stock | $78,747,983 | $61,752,305 | $46,125,397 | $5,934,141 |
| Common Stock | $78,747,983 | $61,752,305 | $46,125,397 | $5,934,141 |
| Current Provisions | $93,521 | $81,852 | $66,899 | - |
| Current Accrued Expenses | $84,684 | $50,481 | $125,951 | $162,557 |
| Investments And Advances | $8,450,686 | $745,000 | $0 | - |
| Other Investments | $389,758 | $0 | - | - |
| Investmentsin Associatesat Cost | $8,060,928 | $0 | - | - |
| Net PPE | $6,059 | $11,096 | $5,487 | $0 |
| Accumulated Depreciation | $-9,774 | $-4,508 | $-240 | $0 |
| Gross PPE | $15,833 | $15,604 | $5,727 | $0 |
| Machinery Furniture Equipment | $15,833 | $15,604 | $5,727 | - |
| Other Properties | - | - | $5,727 | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,643,236 | $-3,744,115 | $-2,951,092 | $-1,592,080 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,143,007 | $-3,734,238 | $-2,945,365 | $-1,592,080 |
| Cash Flow From Continuing Operating Activities | $-8,143,007 | $-3,734,238 | $-2,945,365 | $-1,592,080 |
| Operating Gains Losses | $215,840 | $-519,312 | $28,410 | $-84,499 |
| Investing Activities | ||||
| Capital Expenditure | $-500,229 | $-9,877 | $-5,727 | - |
| Investing Cash Flow | $-4,511,456 | $-16,230 | $-5,727 | $0 |
| Cash Flow From Continuing Investing Activities | $-4,511,456 | $-16,230 | $-5,727 | $0 |
| Net Other Investing Changes | $-11,227 | $-6,353 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $1,742,051 | $0 | $0 |
| Financing Cash Flow | $13,964,060 | $9,152,446 | $2,350,000 | $1,172,923 |
| Cash Flow From Continuing Financing Activities | $13,964,060 | $9,152,446 | $2,350,000 | $1,172,923 |
| Net Common Stock Issuance | $0 | $1,742,051 | $0 | $0 |
| Common Stock Issuance | $0 | $1,742,051 | $0 | $0 |
| Net Other Financing Charges | - | - | - | $1,172,923 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-150,000 | $0 |
| Issuance Of Debt | $13,964,060 | $7,410,395 | $2,500,000 | $0 |
| End Cash Position | $7,444,763 | $6,135,166 | $733,188 | $1,334,280 |
| Beginning Cash Position | $6,135,166 | $733,188 | $1,334,280 | $1,753,437 |
| Changes In Cash | $1,309,597 | $5,401,978 | $-601,092 | $-419,157 |
| Net Issuance Payments Of Debt | $13,964,060 | $7,410,395 | $2,350,000 | $0 |
| Net Short Term Debt Issuance | $0 | $1,000,000 | $2,350,000 | $0 |
| Short Term Debt Payments | $0 | $0 | $-150,000 | $0 |
| Short Term Debt Issuance | $0 | $1,000,000 | $2,500,000 | $0 |
| Net Long Term Debt Issuance | $13,964,060 | $6,410,395 | $0 | $0 |
| Long Term Debt Issuance | $13,964,060 | $6,410,395 | $0 | $0 |
| Net Business Purchase And Sale | $-4,000,000 | $0 | $0 | - |
| Purchase Of Business | $-4,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-500,229 | $-9,877 | $-5,727 | $0 |
| Purchase Of PPE | $-500,229 | $-9,877 | $-5,727 | $0 |
| Change In Working Capital | $-1,216,033 | $-386,203 | $-1,172,951 | $1,477,535 |
| Change In Payables And Accrued Expense | $13,444 | $-360,932 | $-1,035,498 | $1,659,058 |
| Change In Prepaid Assets | $-1,004,061 | $70,330 | $-245,075 | $-71,665 |
| Change In Receivables | $-225,416 | $-95,601 | $107,622 | $-109,858 |
| Other Non Cash Items | $-367,000 | $218,412 | $43,582,435 | - |
| Stock Based Compensation | $155,341 | $0 | $317,882 | $221,287 |
| Unrealized Gain Loss On Investment Securities | $0 | $-4,063,193 | $5,457,667 | $0 |
| Depreciation Amortization Depletion | $5,266 | $4,268 | $240 | $0 |
| Depreciation And Amortization | $5,266 | $4,268 | $240 | $0 |
| Depreciation | $5,266 | $4,268 | $240 | $0 |
| Earnings Losses From Equity Investments | $45,239 | $0 | $0 | - |
| Gain Loss On Investment Securities | $15,380 | $-509,452 | $306,250 | - |
| Net Foreign Currency Exchange Gain Loss | $44,979 | $-9,860 | $3,660 | $-84,499 |
| Gain Loss On Sale Of PPE | $110,242 | $0 | $0 | - |
| Net Income From Continuing Operations | $-6,936,421 | $1,011,790 | $-51,159,048 | $-3,206,403 |
| Gain Loss On Sale Of Business | - | $-22,967 | $0 | $0 |
Fetched: 2026-07-15